InSite Vision Inc., of Alameda, Calif., completed patient enrollment in the Phase III DOUBle (Dual Ophthalmic agents Used in Blepharitis) trial of AzaSite Plus (ISV-502) and DexaSite (ISV-305) in blepharitis. The study enrolled more than 900 patients with moderate to severe blepharitis in a four-arm trial designed to evaluate the efficacy and safety of both product candidates simultaneously.
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Sign up for Perspectives FREE e-mail newsletter